A Phase 1 Investigator Initiated Study to Evaluate the Safety, Tolerability and Preliminary Effectiveness of AB-SA01 in Patients with Chronic Rhinosinusitis Associated with Staphylococcus aureus Infection

Trial Profile

A Phase 1 Investigator Initiated Study to Evaluate the Safety, Tolerability and Preliminary Effectiveness of AB-SA01 in Patients with Chronic Rhinosinusitis Associated with Staphylococcus aureus Infection

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs AB SA01 (Primary)
  • Indications Rhinosinusitis; Staphylococcal infections
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 04 Apr 2017 According to an AmpliPhi Biosciences Corporation media release, data from this trial will be presented at the 2017 Australian Society of Otolaryngology Head and Neck Surgery Meeting.
    • 19 Dec 2016 According to an AmpliPhi Biosciences Corporation media release, detailed results from this trial will be presented at a medical conference in 2017.
    • 19 Dec 2016 Results published in an AmpliPhi Biosciences Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top